| Interpharm Consultancy |
|
|
|
Peter Wittner, who heads Interpharm, previously headed the European sales and marketing department of the UK generics company H.N. Norton, (subsequently part of IVAX). Peter later joined the Indian generic leader Ranbaxy to help set up its UK business and then returned to consultancy work - see website at (http://www.interpharm-consultancy.co.uk/). Interpharm is therefore able to provide help and advice on the basis of extensive generic industry experience. Amongst its services, INTERPHARM:
In addition, Peter has written a number of reports on the generics industry including "Growth Strategies in Generics"," Generics Defense Strategies" and "US and European Prescription Generic Markets" and is a regular contributor to the GenericsWeb newsletter "INNsight".
The European Union (EU) is expanding to include new members and with its expansion the opportunities for generic pharmaceuticals are growing too. With Bulgaria and Romania intending to join the EU in 2007, now is a verygood time for you to look at opportunities for your company in the EU. Competitor companies from India, China and several other East European countries are already moving into the European marketplace. Others are sure to follow soon. It is therefore important for companies interested in this market to act now in order to gain market share.
There is a solution - take the initiative now and look at establishing yourself in Europe either through a subsidiary or finding a distributor for your products. But where should new market entrants start? Interpharm can help you find answers to this question. Interpharm offers you: · In-depth knowledge of the European generic industry · Experience of establishing new generic business in Europe · Experience of working with East European pharmaceutical companies ·Up to date knowledge of the latest European pharmaceutical legislation · Extensive contacts with the major players in the European generic industry · Guidance of how the West European generic environment differs from that which you know We can be your bridge to Western Europe, allowing you to take advantage of the increasing levels of cross-border harmonisation. European generics are going through a major growth phase right now. You can take advantage of this opportunity before your competitors spot what is happening.Contact us now for more information. Read also at Pharmaceutical Licensing NetworkRelated Items
|
| < Prev | Next > |
|---|
Complete your profileThe more information you put into your profile the easier it is for others to find you. Compare your profile with those of other members. The more you put into the network, the more benefit you will derive from community. |